Filter
62
Text search:
Multi-drugresistant
Tuberculosis/MDR-TB
Featured
16
32
Language
Document type
50
7
2
1
1
1
Countries / Regions
6
4
3
3
3
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
33
18
4
1
Toolboxes
36
3
2
1
1
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s
...
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-
...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) increasingly occur in resource-constrained settings
...
For full publication see: https://drtbnetwork.org/mdr-tb-patient-education-flipchart
This tool can be used to educate new patients about TB and MDR-TB. The healthcare provider should review the material together with the patient. A treatment supporter can also use this flipchart at community lev
...
Accessed November 2017
6th edition
UN, international agencies and experts released a groundbreaking report demanding immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis.
If no action is taken - warns the UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance who release
...
The third edition, released in 2018, has grown to include a total of 18 chapters, contributed by 20 experts and authors from many countries. The goal remains the same: to educate primary care providers on the best practices in TB diagnosis, treatment and follow-up. All articles are richly illustrate
...
6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.
District Level M & E Training and Reference Material for Primary Health Care Programmes
This core package of materials provides a comprehensive introduction to the FAST strategy: a focused approach to stopping TB spread in congregate settings. In English, FAST stands for:
Finding TB cases
Actively,
Separating safely, and
Treating effectively.
FAST focuses health care w
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
